Systematic (IUPAC) name | |
---|---|
(4S,6S,12aS)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide OR (4S,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide |
|
Clinical data | |
Trade names | Sumycin |
AHFS/Drugs.com | monograph |
MedlinePlus | a682098 |
Licence data | US FDA:link |
Pregnancy cat. | D(AU) D(US) |
Legal status | ℞ Prescription only |
Routes | oral, topical (skin & eye), im, iv |
Pharmacokinetic data | |
Bioavailability | 60-80% Oral, while fasting <40% Intramuscular |
Metabolism | Not metabolised |
Half-life | 6-11 hours |
Excretion | Fecal and Renal |
Identifiers | |
CAS number | 60-54-8 64-75-5 (hydrochloride) |
ATC code | A01AB13 D06AA04 J01AA07 S01AA09 S02AA08 S03AA02 QG01AA90 QG51AA02 QJ51AA07 |
PubChem | CID 643969 |
DrugBank | DB00759 |
ChemSpider | 10257122 |
UNII | F8VB5M810T |
KEGG | D00201 |
ChEBI | CHEBI:27902 |
ChEMBL | CHEMBL1440 |
Chemical data | |
Formula | C22H24N2O8 |
Mol. mass | 444.435 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Tetracycline (INN) ( /ˌtɛtrəˈsaɪkliːn/) is a broad-spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria, indicated for use against many bacterial infections. It is a protein synthesis inhibitor. It is commonly used to treat acne today, and, more recently, rosacea, and is historically important in reducing the number of deaths from cholera. Tetracycline is marketed under the brand names Sumycin, Tetracyn, and Panmycin, among others. Actisite is a thread-like fiber formulation used in dental applications. It is also used to produce several semisynthetic derivatives, which together are known as the tetracycline antibiotics. The term "tetracycline" is also used to denote the 4-ring system of this compound; "tetracyclines" are related substances that contain the same 4-ring system.
Contents |
Tetracyclines bind to the 30S subunit of microbial ribosomes. They inhibit protein synthesis by blocking the attachment of charged aminoacyl-tRNA. Thus, they prevent introduction of new amino acids to the nascent peptide chain.[1] The action is usually inhibitory and reversible upon withdrawal of the drug. Resistance to the tetracyclines results from changes in permeability of the microbial cell envelope. In susceptible cells, the drug is concentrated from the environment and does not readily leave the cells. In resistant cells, the drug is not actively transported into the cells or leaves it so rapidly that inhibitory concentrations are not maintained. This is often plasmid-controlled. Mammalian cells are not vulnerable to the effect of tetracyclines, as these contain no 30S ribosomal subunits and therefore do not accumulate the drug.
The tetracyclines are a large family of antibiotics that were discovered as natural products by Benjamin Minge Duggar and first described in 1948.[2] Under Yellapragada Subbarao, Benjamin Duggar made his discovery of the first tetracycline antibiotic, chlortetracycline (Aureomycin), at Lederle Laboratories in 1945.[3]
In 1950, Harvard Professor Robert Woodward determined the chemical structure of the related substance, oxytetracycline (Terramycin); the patent[4] protection for its fermentation and production was also first issued in 1950. A research team of seven scientists (K.J. Brunings, Francis A. Hochstein, C.R. Stephens, L.H. Conover, Abraham Bavley, Richard Pasternack, and Peter P. Regna) at Pfizer,[5][6] in collaboration with Woodward, participated in the two-year research leading to the discovery.[7]
Pfizer was of the view that it deserved the right to a patent on tetracycline and filed its Conover application in October 1952. Cyanamid filed its Boothe Morton application for similar rights in March 1953, while Heyden Chemicals filed its Minieri application in September 1953, named after scientist P. Paul Minieri, to obtain a patent on tetracycline and its fermentation process. This resulted in tetracycline litigation in which the winner would have to prove beyond reasonable doubt of priority invention and tetracycline’s natural state.[8]
Nubian mummies studied in the 1990s were found to contain significant levels of tetracycline; there is evidence that the beer brewed at the time could have been the source.[9] Tetracycline sparked the development of many chemically altered antibiotics, so has proved to be one of the most important discoveries made in the field of antibiotics. It is used to treat many Gram-positive and Gram-negative bacteria and some protozoa. Like some other antibiotics, it is also used in the treatment of acne.
Are as those of the tetracycline antibiotics group:
In 2010, the FDA added tetracycline to its Adverse Event Reporting System (AERS).[11] The AERS contains a list of medications under investigation by the FDA for potential safety issues. The list is published quarterly and available online. The AERS cites a potential link between the use of tetracycline products and Stevens–Johnson syndrome, toxic epidermal necrolysis and erythema multiforme.[11]
It is first-line therapy for Rocky Mountain spotted fever (Rickettsia), Q fever (Coxiella), psittacosis and lymphogranuloma venereum (Chlamydia), and to eradicate nasal carriage of meningococci. Tetracycline tablets were used in the plague outbreak in India in 1992.[12]
Doxycycline is also one (of many) recommended drugs for chemoprophylatic treatment of malaria in travels to areas of the world where malaria is endemic.[13]
Since tetracycline is absorbed into bone, it is used as a marker of bone growth for biopsies in humans. Tetracycline labeling is used to determine the amount of bone growth within a certain period of time, usually a period of approximately 21 days. Tetracycline is incorporated into mineralizing bone and can be detected by its fluorescence.[14] In "double tetracycline labeling", a second dose is given 11–14 days after the first dose, and the amount of bone formed during that interval can be calculated by measuring the distance between the two fluorescent labels.[15]
Tetracycline is also used as a biomarker in wildlife to detect consumption of medicine- or vaccine-containing baits.[16]
In genetic engineering, tetracycline is used in transcriptional activation. Tetracycline is also one of the antibiotics used to treat ulcers caused by bacterial infections. In cancer research at Harvard Medical School, tetracycline has been used to switch off leukemia in genetically altered mice, and to do so reliably, when added to their drinking water.[17]
Tetracycline is used in cell biology as a selective agent in cell culture systems. It is toxic to prokaryotic and eukaryotic cells and selects for cells harboring the bacterial tetr gene, which encodes a 399-amino acid membrane-associated protein. This protein actively exports tetracycline from the cell, rendering cells harboring this gene more resistant to the drug. The yellow crystalline powder can be dissolved in water (20 mg/ml) or ethanol (5 mg/ml), and is routinely used at 10 mg/l in cell culture. In cell culture at 37 °C (99 °F), it is stable for days, with a half-life of approximately 24 hours.
|
|
|
|
|